Aragen Life Sciences IPO infographic with fresh issue size and capacity expansion

The Aragen Life Sciences IPO took a step closer this week after the Hyderabad contract research and manufacturing firm told Reuters on November 18, 2026, that it plans to spend about Rs 150 crore (1.5 billion rupees, roughly $16 million) over two years to expand drug development and manufacturing, alongside a public issue that includes a Rs 800 crore fresh share sale. For investors tracking India’s pharma services boom, here is what the numbers show and what is still missing.

Key takeaways on the Aragen Life Sciences IPO

  • The IPO combines a Rs 800 crore fresh issue with an offer for sale of up to 2,73,29,192 shares by existing holders.
  • The draft red herring prospectus was filed with SEBI in late August 2026; price band, dates and lot size are not yet announced.
  • Aragen reported FY26 revenue from operations of Rs 2,178.39 crore and profit of Rs 257.64 crore.
  • Expansion plans: small-molecule capacity from 364 kL to 650 kL, and biologics capacity from 2.5 kL to 8.5 kL by next year.
  • About 65% of revenue still comes from drug discovery services, with 591 customers.

What Aragen does and why it matters

Aragen, founded in 2000 and formerly known as GVK Biosciences, is a CRDMO: it helps drugmakers discover molecules, develop them and then manufacture them. According to its draft prospectus summaries, it worked with 16 of the world’s top 20 pharma companies as of March 31, 2026. Its biologics arm, Aragen Biologics, runs a facility in Bengaluru, while chemistry and manufacturing are concentrated in Hyderabad.

Indian CRDMOs are winning more work as global companies diversify supply chains away from China, a trend Aragen’s managing director and CEO Manmahesh Kantipudi pointed to when he told Reuters there is “a lot of headroom to grow” in development and manufacturing. Listed peers such as Syngene and Sai Life Sciences are chasing the same demand.

Expansion plan in numbers

AreaCurrentTargetChange (by our calculation)
Small-molecule reactor capacity364 kL650 kL+79%
Biologics capacity2.5 kL8.5 kL3.4 times
Spend on CDMO (development and manufacturing)About Rs 100 croreTwo of every three rupees planned
Spend on discovery and contract researchAbout Rs 40 croreRemainder of plan

The tilt matters. Discovery services bring in most of Aragen’s revenue today, but manufacturing contracts tend to be larger and stickier once a molecule reaches late-stage trials or launch. Shifting capital toward CDMO is a bet that some of Aragen’s 591 discovery clients will keep their molecules with the company as they advance.

Financial snapshot

Metric (FY26)Value
Revenue from operationsRs 2,178.39 crore
Profit for the yearRs 257.64 crore
Adjusted EBITDARs 593.77 crore
Return on capital employed18.18%
Return on equity11.96%

By our calculation, the adjusted EBITDA margin works out to about 27% of revenue, and net profit to just under 12%. Prospectus summaries show profit rising from about Rs 180 crore in FY25, a gain of roughly 43%.

Where the IPO money goes

Only the fresh issue reaches the company. Aragen says it will use those funds to repay or prepay borrowings, buy equipment for its Hyderabad sites, fund capex by Aragen Biologics in Bengaluru, and for general corporate purposes. The offer-for-sale shares come from existing investors; prospectus summaries list Singapore-based WSCPVIII entities and Goldman Sachs Capital Holdings III among the larger sellers, alongside promoter-group holders. Lead managers are Axis Capital, Citigroup Global Markets India, Goldman Sachs (India) Securities and JM Financial, and the shares are proposed for listing on the BSE and NSE.

Why the timing works for Indian CRDMOs

Three forces are lining up behind the listing. Global drugmakers want second sources outside China for both chemistry and biologics. Indian regulators and the US FDA are pushing harder on manufacturing quality, which tends to favour larger, well-audited service providers over small plants. And Indian public markets have rewarded pharma services stocks with strong demand for recent listings. None of that guarantees Aragen a warm reception, but it explains why the company is choosing this window to raise capital and expand capacity at the same time.

Market context

Aragen’s biologics push targets one of the faster-growing parts of outsourcing. Acumen Research and Consulting values the global biologics CDMO market at $34.26 billion in 2025 and $38.71 billion in 2026, and expects it to reach $96.85 billion by 2035, a 10.7% compound annual growth rate. Asia-Pacific is projected to grow fastest, at 12.9% a year, while monoclonal antibodies, including bispecifics, made up 56% of the market in 2025. A tripling of biologics capacity places Aragen squarely in that segment, though from a small base.

What investors still do not know

  • The price band and therefore the valuation multiple.
  • Issue dates and the final IPO size, which depends on the OFS price.
  • How quickly new capacity converts into signed manufacturing contracts.
  • Client concentration and the effect of US policy shifts, such as moves to curb work with certain Chinese biotech suppliers, on Indian CRDMO order books.

Frequently asked questions

When will the Aragen Life Sciences IPO open?

Dates have not been announced. The company filed its draft prospectus with SEBI in August 2026, and the price band, lot size and schedule will be set later.

What is the Aragen IPO size?

It includes a Rs 800 crore fresh issue plus an offer for sale of up to 2.73 crore shares. The total value depends on the price band.

Is Aragen profitable?

Yes. It reported FY26 profit of Rs 257.64 crore on revenue from operations of Rs 2,178.39 crore.

What does a CRDMO do?

A contract research, development and manufacturing organisation handles discovery chemistry and biology, process development and production for drugmakers that outsource those steps.

Read more on India’s pharma manufacturing shifts: FDA unannounced inspections in India, Shilpa CDMO’s peptide expansion, and our pharmaceutical news section.

Sources: Reuters interview with Aragen (Nov 18, 2026); Aragen DRHP summaries reported by Business Today. Market data: Acumen Research and Consulting. This article is for information only and is not medical or investment advice. Last updated November 19, 2026.

By Simone Lamb

Simone Lamb is the editor of Medgadget.in, covering healthcare technology, medical devices, and the latest developments in digital health.

Leave a Reply

Your email address will not be published. Required fields are marked *